A5033560706- Biosimilars and Bioanalytical Methods
- Advanced Biosensing Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Fatty Acid Research and Health
- CAR-T cell therapy research
- Thermochemical Biomass Conversion Processes
- Virus-based gene therapy research
- Biosensors and Analytical Detection
- Computational Drug Discovery Methods
- Viral Infections and Immunology Research
- Gas Sensing Nanomaterials and Sensors
- Muscle metabolism and nutrition
- Advanced Chemical Sensor Technologies
- Cholesterol and Lipid Metabolism
- Advanced biosensing and bioanalysis techniques
- Lipid metabolism and biosynthesis
- Diet and metabolism studies
- Statistical Methods in Clinical Trials
- Coal and Its By-products
- Adsorption and biosorption for pollutant removal
- Coconut Research and Applications
- Coal Properties and Utilization
- Topic Modeling
- Bioinformatics and Genomic Networks
- Speech Recognition and Synthesis
REVA University
2025
Alzheimer's Drug Discovery Foundation
2019-2021
Biogen (United States)
2013-2020
UCB Pharma (United Kingdom)
2016-2017
Central Food Technological Research Institute
1992-2003
University of Cincinnati
1999-2001
Western Kentucky University
1996-1999
Antibody-drug conjugates (ADCs) typically consist of a cytotoxic drug covalently bound to an antibody by linker. These have the potential substantially improve efficacy and reduce toxicity compared with small-molecule drugs. Since ADCs are generally complex heterogeneous mixtures multiple species, these novel therapeutic products present unique bioanalytical challenges. The growing number being developed across industry suggests need for alignment methods or approaches used assess species...
The 2019 13th Workshop on Recent Issues in Bioanalysis (WRIB) took place New Orleans, LA, USA April 1–5, with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event – full immersion week bioanalysis, biomarkers, immunogenicity gene therapy. As usual, it specifically designed to facilitate sharing, reviewing, discussing agreeing...
Evolving immunogenicity assay performance expectations and a lack of harmonized anti-drug antibody validation testing reporting tools have resulted in significant time spent by health authorities sponsors on resolving filing queries. Following debate at the American Association Pharmaceutical Sciences National Biotechnology Conference, group was formed to address these gaps. Over last 3 years, 44 members from 29 organizations (including 5 Europe 10 FDA) discussed gaps understanding...
The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held 27 September to 1 October 2021. Even with a last-minute move from in-person virtual, an overwhelmingly high number nearly 900 professionals representing pharma and biotech companies, contract research organizations (CROs), multiple regulatory agencies still eagerly convened actively discuss most current topics interest bioanalysis. WRIB included 3 Main Workshops 7 Specialized that together spanned week...
Promethazine hydrochloride (PMHC) is a vital drug that used as an anticholinergic, antipsychotic, antihistaminic, analgesic, sedative, and neuroleptic. However, the overdosage of PMHC also causes reproductive variations, cardiac changes, hypotension, endocrinal variations. Hence, detection crucial. Therefore, in this work electrochemical method for reported. The fabrication modified electrode built with tungsten (W), nickel (N), strontium (S) ternary oxide (tWNSO). To best our knowledge,...
The goal of this article is to discuss the fundamental key questions around parallelism assessments: why do it, when it and how with consideration for different molecule types scientific rationale that drives approaches. Current practices both PK biomarker assays regarding which samples pick, whether pool or not samples, as well generally accepted acceptance criteria are discussed, while also highlighting many outstanding remain. In order reach long-term understanding developing best...
Anti-drug antibodies (ADA) pose a potential risk to patient safety and efficacy are routinely monitored during clinical trials. Pre-existing drug-reactive present in patients without prior drug exposure defined by their ability bind component of the drug. These pre-existing frequently observed could represent an adaptive immune response individual who has been previously exposed antigens with structural similarities biotherapeutic. Clinical consequences these can vary from no impact adverse...
A bead based sandwich enzyme immunoassay coupled to electrochemical detection for ovalbumin has been developed. The label alkaline phosphatase was used convert the substrate 4-aminophenyl phosphate electroactive product 4-aminophenol. done in a microdrop by continuously monitoring turnover with rotating disk electrode. This reduces dilution of product, key achieving low limits. assay developed limit 0.1 ng ml−1. Assay sensitivity complex matrices such as food and serum compared.